Close Menu

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics has filed a prospectus for an initial public offering of its stock for up to $60 million. 

The Tucson, Ariz.-based firm has not priced its shares nor said how many shares it plans to offer. It said in its Form S-1 filed with the US Securities and Exchange Commission on Tuesday that it plans to trade its stock on the Nasdaq Global Market under the ticker symbol "HTGM." 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.